Reports

221 Results (Page 1 of 9)

Japan Markets Research Reports

Pharmaceuticals

Japan Dermatological Therapeutics Market Analysis

Japan Dermatological Therapeutics Market is at around $2.56 Bn in 2023 and is projected to reach $4.71 Bn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The market is being driven by an increasing aging population, a growing prevalence of dermatological disorders, and technological advancements in treatment options. The market is dominated by key players like Takeda Pharmaceutical Company Limited (JPN), Shionogi & Co., Ltd. (JPN), Eisai Co., ltd. (JPN), Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson, and GlaxoSmithKline Plc.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Alopecia (Hair Loss) Therapeutics Market Analysis

The Japan Alopecia (Hair Loss) Therapeutics Market was valued at US $510 Mn in 2022, and is predicted to grow at (CAGR) of 8% from 2023 to 2030, to US $943 Mn by 2030. The primary factors propelling this industry forward include the notable increase in the prevalence of Alopecia (hair loss), technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Lexington, Sun Pharmaceuticals, Merck, Capillus, and Follica Inc., among others.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Digital Health

Japan Digital Therapeutics Market Analysis

Japan Digital Therapeutics Market is at around $0.4 Bn in 2023 and is projected to reach $2.14 Bn in 2030, exhibiting a CAGR of 27.7 % during the forecast period. The market is growing as a result of rising prevalence of chronic diseases, an aging population, and government initiatives. The market is dominated by key players like CureApp Co., Ltd., Ubie, Inc., Apple Inc., Omada Health Inc., 2Morrow Inc., Livongo Health Inc., WellDoc, Propeller Health, Canary Health, and Noom Inc.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Allergy Therapeutics Market Analysis

Japan Allergy Therapeutics Market was valued at $1442 Mn in 2022 and is estimated to reach $2459 Mn in 2030, exhibiting a CAGR of 6.9% during the forecast period. The increased incidence of allergic illnesses and associated health issues is driving the need for allergy therapy medications. The major pharmaceutical players that are presently functioning in the market are Eisai Co., Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Kowa Pharmaceutical Co., and Daiichi Sankyo Co.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Alcohol Addiction Therapeutics Market Analysis

The Japan Alcohol Addiction Therapeutics Market is valued at around $44 Mn in 2022 and is projected to reach $75 Mn by 2030, exhibiting a CAGR of 6.8% during the forecast period. Japan's market growth is propelled by government acknowledgment, increased mental health funding, and a rising demand for more effective and tolerable novel therapies to address the challenges posed by alcohol misuse in an aging population. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in Japan are Lundbeck, AstraZeneca, Alkermes, Merck & Co., TEVA Pharmaceuticals, Pfizer, BioCorRx, Otsuka, Kyorin, Eisai etc among others.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Cardiovascular Drugs Market Analysis

Japan Cardiovascular Drug Market is at around $8.56 Bn in 2022 and is projected to reach $12.04 Bn in 2030, exhibiting a CAGR of 4.30% during the forecast period. Due to changes in modern lifestyle, the prevalence of cardiovascular disease has been rising. The market is dominated by key players like Otsuka Holdings Co Ltd., Takeda Pharmaceutical Co Ltd., Daiichi Sankyo Co Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, and Novartis AG.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Actinic Keratosis Therapeutic Market Analysis

According to estimates, the Japan Actinic Keratosis Therapeutic Market will reach around $644 Mn by 2030, up from $423 Mn in 2022, rising at a CAGR of 5.4% during the forecast period. Actinic keratosis treatments are becoming increasingly popular as individuals become more aware of the dangers of sun exposure and the significance of regular skin care. Almirall, LEO Pharma, Sun Pharmaceuticals, Novartis, Galderma, Bausch Health, Biofrontera, and others are among the leading industry competitors in the Japan Actinic Keratosis Therapeutic Market

PUBLISHED: Jan, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis

The Japan Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $205 Mn in 2022, and is predicted to grow at (CAGR) of 8.3% from 2023 to 2030, to US $388 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic leukemia cases, technological advancements, increased government funding initiatives, and other factors. The industry is primarily dominated by players such as Astella, Takeda, Eisai, Daiichi Sankyo among other players

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Japan Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $68 Mn in 2022 and is predicted to grow at a CAGR of 6.3% from 2023 to 2030, to US $111 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, collaborations, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Age-Related Macular Degeneration Therapeutics Market Analysis

The Japan Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $671 Mn in 2022, and is predicted to grow at a CAGR of 9.40% from 2023 to 2030, to US $1.377 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Addiction Therapeutics Market Analysis

Japan addiction therapeutics market was valued at $628 Mn in 2022 and is estimated to reach $1111 Mn in 2030, exhibiting a CAGR of 7.4% during the forecast period. The increasing awareness and recognition of mental health issues, such as substance abuse and addiction, has led to a sharp increase in the market for addiction therapies. A few prominent entities in the addiction therapeutics industry comprise Takeda Pharmaceutical Company, Astellas Pharma Inc., Daiichi Sankyo Company, Eisai Co., Otsuka Pharmaceutical Co., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Chugai Pharmaceutical Co., Kyowa Kirin Co., and Sumitomo Dainippon Pharma

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Adult Malignant Glioma Therapeutics Market Analysis

The Japan Adult Glioma Therapeutics Market is valued at around $137 Mn in 2022 and is projected to reach $281 Mn by 2030, exhibiting a CAGR of 9.4% during the forecast period. A progressive healthcare system, active involvement in clinical research, increasing patient awareness, and cooperative efforts amongst pharmaceutical firms are all contributing factors to the growth of the Japan Adult Malignant Glioma Therapeutics Market. Key players in the Japan Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Eisai, Otsuka Pharmaceuticals, Chugai Pharmaceuticals, Taiho Pharmaceuticals, and Novocure etc.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Japan Oncology Drugs Market Analysis

By 2030, it is anticipated that the Japan oncology drugs market will reach a value of $30.4 Bn from $12.2 Bn in 2022, growing at a CAGR of 12.1% during 2022-30. The companies operating in the oncology drug in Japan market are Taiho Pharmaceutical Group, Daiichi Sankyo, and Kyowa Kirin. The Japan oncology drugs market is segmented based on therapy modality and types of cancer. The main drivers of the growth of the Japanese oncology drugs market are the rise in cancer incidence, the explosion in research into new drugs for cancer treatment, and the rise in healthcare spending.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Japan Neurology Devices Market Analysis

Japan's Neurology Device Market size is at around $784.44 Mn in 2022 and is projected to reach $1484.53 Bn in 2030, exhibiting a CAGR of 8.3% during the forecast period. Artificial intelligence machine learning in neurology diagnostics, and 3D printing for customizing and improving neurology devices are the major trends in medical devices in Japan reigned by players like B. Braun Melsungen, Stryker, and Boston Scientific. This report by Insights10 is segmented by product type like neurostimulation, interventional neurology, neurosurgery devices, and neuro-endoscopes, and by the end user.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Japan Insulin Market Analysis

This report presents a strategic analysis of the Japan Insulin Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Japan Insulin Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Japan ENT Devices Market Analysis

Japan's ENT Devices Market is projected to grow from $1.44 Bn in 2022 to $2.34 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. The domestic key players in the Japan ENT devices market include Olympus Corporation, Fukuda Denshi, and HOYA Corporation.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Japan Coronary Stents Market Analysis

Japan's Coronary Stents Market is expected to witness growth from $702 Mn in 2022 to $1058 Mn in 2030 with a CAGR of 5.25% for the forecasted year 2022-30. The early identification and treatment of coronary artery disease in Japan are projected to be driven by increased access to healthcare and improved heart health awareness, opening up the potential for manufacturers in the coronary stent market. The market is segmented by type, mode of delivery, materials, and end user. Some key players in this market include Terumo Corporation, Fukuda, B. Braun, Abbott Laboratories, Biotronik, Medtronic, GE Healthcare, Boston Scientific, and Philips Healthcare.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Healthcare Services

Japan Clinical Diagnostics Market Analysis

This report presents a strategic analysis of the Japan Clinical Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Japan Clinical Diagnostics Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Japan Cardiovascular Diseases Therapeutics Market Analysis

Japan's cardiovascular disease therapeutics market is projected to grow from $10.10 Bn in 2022 to $18.32 Bn in 2030 with a CAGR of 7.72% for the year 2022-30. Japan has the largest elderly population which results in an increased demand for cardiovascular therapeutics in Japan hence driving the growth of the market. The Japan cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end user. Kewpie Corporation, Morunda, and Pfizer are the major players in the Japanese cardiovascular disease therapeutics market.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Japan Cancer Immunotherapy Market Analysis

Japan's cancer immunotherapy market is expected to witness growth from $6.9 Bn in 2022 to $12.5 Bn in 2030 with a CAGR of 7.6% for the forecasted year 2022-30. The rise in the aging population of Japan and the more comprehensive and supportive regulatory policies for drug approvals are driving the growth of the market. The Japanese cancer immunotherapy market is segmented by type, application, and end user. Modulus Discovery, Noile-Immune Biotech, and Bayer are the major players in the Japanese cancer immunotherapy market.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

OTC & Nutraceuticals

Japan Over The Counter (OTC) Pharmaceuticals Market Analysis

Japan's over-the-counter (OTC) pharmaceuticals market size was valued at $8546.8 Mn in 2022 and is estimated to expand at a CAGR of 6.04% from 2022 to 2030 and will reach $13663.5 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. The key market players are Johnson and Johnson Services Inc (USA), Bayer AG (Germany), Novartis AG (Switzerland) and others.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Nov, 2023 | PRICE: $3999

Pharmaceuticals

Japan Alzheimer’s Disease Drugs Market Analysis

Japan's Alzheimer’s disease drugs market was valued at $958 Mn in 2022 and is estimated to expand at a CAGR of 8.92% from 2022-30 and will reach $1899 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson., Novartis AG, Pfizer, Takeda Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, Otsuka Holdings Co, Shionogi & Co among others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Oct, 2023 | PRICE: $3999

Pharmaceuticals

Japan Alexipharmic Drugs Market Analysis

Japan's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 5.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Japan Alexipharmic Drugs market will grow because the government and healthcare providers are increasing their efforts to raise public awareness about poisoning and the availability of antidotes. The key market players are Takeda Pharmaceutical (JPN), Astellas Pharma (JPN), Eisai (JPN), Daiichi Sankyo (JPN), Otsuka Pharmaceutical (JPN), Chugai Pharmaceutical (JPN), and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Oct, 2023 | PRICE: $3999

Pharmaceuticals

Japan Radiotherapy Market Analysis

By 2030, it is anticipated that the Japan Radiotherapy Market will reach a value of $711 Mn from $430 Mn in 2022, growing at a CAGR of 6.5% during 2022-30. The Radiotherapy Therapeutics Market in Japan is dominated by a few domestic players such as Hitachi, Mitsubishi Electric Corporation, and IHI Corporation. The radiotherapy market in Japan is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Japan Radiotherapy is increasing on account of the rise in cancer cases in the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Oct, 2023 | PRICE: $3999

Healthcare Services

Japan Patient Engagement Solutions Market Analysis

Japan's patient engagement solutions market is projected to grow from $1.06 Bn in 2022 to $2.75 Bn by 2030, registering a CAGR of 12.7% during the forecast period of 2022-30. The main factors driving the growth would be technological advancements, increasing healthcare spending, the aging population, government support, and changing patient preferences. The market is segmented by component, delivery mode, application, therapeutic area, functionality, and end-user. Some of the major players include CureApp, Takeda Pharmaceutical, NTT Data, M3 and Oracle.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Oct, 2023 | PRICE: $3999

subscribe to our newsletter
up